This tumor board will discuss how to select the most appropriate therapy for patients with non-small cell lung cancer (NSCLC) using a case-based format. New targeted therapy regimens are being rapidly approved for patients with metastatic NSCLC and have been shown to improve outcomes for these patients.

Pharmacists should be aware of the treatment recommendations for this rare disease type so they can support patients as well as the health care team in making informed treatment decisions. It is also important to be aware of the potential adverse events that can occur with these therapies since pharmacists frequently provide patient education and monitoring related to this in order to avoid severe complications and maximize treatment outcomes.

Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define how to best improve outcomes while reducing adverse effects, with total neoadjuvant therapy among the approaches of recent interest. Clinicians can benefit from education on relevant clinical trial results related to trimodal therapy for localized rectal cancer and guidance on how these data may be best applied to clinical practice.

It is important to inform clinicians about this new section of the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, which include recommendations for the evaluation, management, and surveillance of well-differentiated G3 NETs. Keeping clinicians abreast of updated treatment options may help improve clinical decision-making to better address patients’ medical needs.